Vyne Therapeutics Inc. · NASDAQ:VYNE
Vyne Therapeutics — Investor Presentation (August 2021)
6 slides from Vyne Therapeutics's investor presentation, Aug 12, 2021
Slide 1: Investor Presentation August 2021
INVESTOR PRESENTATION August 2021 Exhibit 99.3
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the development and commercialization of VYNE’s products and product candidates and other
Slide 3: VYN201 and VYN202 BETi in Immunodermatology / Immunology and Inflammation
Confidential – For Internal Use Only. VYN201 and VYN202 Bromodomain & Extra-Terminal Domain Inhibition (BETi) in Immunodermatology / Immunology and Inflammation 3
Slide 4: BET Protein Family
Confidential – For Internal Use Only. 4 Bromodomain & Extra-Terminal Domain Protein Family (BET) • BET family of proteins comprise of BRD2, BRD3, BRD4 and BRDT*. The BET proteins are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4 and regulate chromatin
Slide 5: BET Proteins – Role in NF-kB transcription in inflammatory disease
5 Bromodomain & Extra-Terminal Domain Proteins – Role in NF-ƙB transcription in inflammatory disease Cytosol P Iƙƙβ Iƙƙa Iƙƙy NF-ƙβ kinase complex activation Activation and translocation of RELA (p65) P Iƙβ p65 p50 Nucleus P p65 p50 Inactive gene ƙB promoter Inhibition of cytokine transcription Cyto
Slide 6: BET Inhibitor Strategy Targeting BRD4
Confidential – For Internal Use Only. BET Inhibitor Strategy Targeting BRD4 6 Bromodomain & Extra Terminal protein with two bromodomains (BDI and BDII) BDI BDII Topical VYN201 binds to both BDI and BDII Oral VYN202 binds to BDII only VYN201 Topical “soft” Pan-BD BET inhibitor Broad activity • Possib
VYNE Therapeutics — Investor Presentation (August 2021) on 6ix